Dialogue Volume 14 Issue 3 2018 - Page 2

MD Vol. 14, Issue 3, 2018 In This Issue D I A LO G U E , V O L . 1 4 , I S S U E 3 , 2 0 1 8 is the official publication of the College of Physicians and Surgeons of Ontario. The objective of this magazine is to provide clear policy direction and review pertinent legislative and disciplinary information, consult with the profession on issues of concern, and provide a forum for discussion and exchange of information and ideas. This publication does not accept unsolicited manuscripts. Dr. Nancy Whitmore REGISTRAR Dr. Nancy Whitmore DEPUTY REGISTRAR Dan Faulkner DIRECTOR, POLICY AND COMMUNICATIONS Louise Verity SENIOR EDITOR Jill Hefley MANAGING EDITOR Elaine McNinch ASSOCIATE EDITOR Tracey Sobers ART DIRECTOR Ally Tripkovic PRINTED IN CANADA BY Mi5 Print & Digital WEBSITE: www.cpso.on.ca 80 College St., Toronto, ON, Canada M5G 2E2 7 Tel: (416) 967-2600 Toll Free: (800) 268-7096 Fax: (416) 961-8035. The College of Physicians and Surgeons of Ontario is the licensing and regulatory body governing the practice of medicine in Ontario. The College is responsible for setting and maintaining medical standards, licensing physicians, investigating complaints about physicians on behalf of the public, and disciplining doctors found to have committed act(s) of professional misconduct. Features 7 Meet the New Registrar  In a Q & A feature, Dr. Nancy Whitmore explains where she thinks the greatest gains in patient protection can be realized. She also discusses the importance of fostering a collaborative relationship with the profession. 9 Managing Low Risk Complaints  In 2017, the median length to provide a decision in a public complaint was 202 days. We think that is too long and does not serve the interests of either complainants or physicians. We discuss our plan for change. Dialogue is published 4 times a year. The subscription rate is included in the annual membership fee and is $36.00. Publication Mail Agreement #40063319 ISSN 1715-8966 15 College’s Opioid Strategy  Council has approved a new direction in its opioid strategy – one that puts the focus squarely on the promotion of quality improvement.